About This Episode
Existing drugs can sometimes be repurposed to treat rare diseases. But making that match can be hard — and the financial incentives are weak. Guest host Steve Levitt tries to solve the puzzle. SOURCES: Chris Snyder, professor of economics at Dartmouth College. David Fajgenbaum, co-founder and president of Every Cure, physician-scientist at the University of Pennsylvania. Heather Stone, health science policy analyst at the Food & Drug Administration. Sarrin Chethik, senior policy analyst at the M
Comments (0)
No comments yet
Be the first to share your thoughts



